Dr. Angela M. Dimango, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York Downstate Medical Center (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 529
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: State University of New York Downstate Medical Center
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NY license 186644 -
Critical Care Medicine (Internal Medicine) Physician
NY license 186644
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- New York-Presbyterian Hospital New York, NY
Medical groups
- Trustees of Columbia University in The City of New York (2,296 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 529
- Services billed
- 1,358
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 418 | 308 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 382 | 83 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 197 | 53 |
| Established patient office or other outpatient visit, 40-54 minutes | 174 | 155 |
| Established patient office or other outpatient visit, 20-29 minutes | 108 | 100 |
| Critical care, first 30-74 minutes | 96 | 17 |
| Test to measure expiratory airflow and volume | 91 | 89 |
| New patient office or other outpatient visit, 60-74 minutes | 61 | 61 |
| Test to measure rate of airflow | 57 | 57 |
| Test to examine how well the lungs exchange gases | 52 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in New York, NY | 210 |
| Prednisone Other prescribers in New York, NY | 189 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in New York, NY | 160 |
| Breo Ellipta (fluticasone/vilanterol) Other prescribers in New York, NY | 122 |
| Azithromycin Other prescribers in New York, NY | 103 |
| Montelukast Sodium Other prescribers in New York, NY | 91 |
| Incruse Ellipta (umeclidinium bromide) Other prescribers in New York, NY | 80 |
| Fluticasone-Salmeterol (fluticasone propion/salmeterol) Other prescribers in New York, NY | 79 |
| Doxycycline Hyclate Other prescribers in New York, NY | 75 |
| Famotidine Other prescribers in New York, NY | 72 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 7 payments worth $1,633 in total to this clinician.
| Insmed, Inc. | $1,545 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $44.84 |
| GlaxoSmithKline, LLC. | $43.82 |
| Consulting Fee | $1,509 |
|---|---|
| Food and Beverage | $107 |
| Education | $17.38 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Insmed, Inc. Apr 11, 2025 | Consulting Fee | $1,509 |
| Insmed, Inc. Sep 4, 2025 | Education Brinsupri; Brinsupri · Respiratory · in-kind | $17.38 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $29,361 in research payments for these studies, mostly to the institutions running them.
- ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
Mannkind Corporation · Terminated · NCT06418711 - A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIR…
Boehringer Ingelheim International GmbH
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.